Opinion

Video

Exploring Real-World Evidence Presented at ATA 2023

Author(s):

Lori J. Wirth, MD,Francis Worden, MD

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
The University of California San Francisco
November 11th 2024

UC Regents Approve UCSF Proton Therapy Center for Cancer Care

D. Ross Camidge, MD, PhD; Douglas Ney, MD, professor, neurology and neurosurgery, program director, Neurology Residency Program, vice-chair, Education, Department of Neurology, University of Colorado Cancer Center
October 23rd 2024

Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD

Hope Rugo, MD, FASCO, of UCSF Helen Diller Family Comprehensive Cancer Center
October 31st 2024

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Manali Kamdar, MD, associate professor, medicine and hematology-oncology, clinical director, Lymphoma Services, University of Colorado Anschutz School of Medicine
August 13th 2024

Subgroup Analysis Makes the Case for Earlier Liso-Cel Administration in R/R MCL

Dr Wells Messersmith, Chief Medical Officer, Oncology Services, UCHealth University of Colorado Hospital
August 8th 2024

Colorado School of Public Health Launches Innovative Program to Support Working Cancer Patients